1992
DOI: 10.1007/978-3-642-77633-5_36
|View full text |Cite
|
Sign up to set email alerts
|

Collaboration of PIM-1 and BCL-2 in Lymphomagenesis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
54
0

Year Published

1996
1996
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 41 publications
(57 citation statements)
references
References 10 publications
3
54
0
Order By: Relevance
“…Overexpression of these proteins greatly increases the clonogenic survival of at least some tumour cells (Strasser et al, 1994a) and deregulated expression of bcl-2 is lymphomagenic (McDonnell and Korsmeyer, 1991;Strasser et al, 1993;Linette et al, 1995), especially in conjunction with overexpression of proto-oncogenes that promote cell proliferation, such as c-myc and pim-1 (Strasser et al, 1990;Acton et al, 1992). The development of an antagonist capable of inhibiting all functional homologues of Bcl-2 and thereby enhancing sensitivity to apoptosis therefore holds great promise for the treatment of neoplastic disease, particularly in combination with other therapeutic regimes.…”
Section: Discussionmentioning
confidence: 99%
“…Overexpression of these proteins greatly increases the clonogenic survival of at least some tumour cells (Strasser et al, 1994a) and deregulated expression of bcl-2 is lymphomagenic (McDonnell and Korsmeyer, 1991;Strasser et al, 1993;Linette et al, 1995), especially in conjunction with overexpression of proto-oncogenes that promote cell proliferation, such as c-myc and pim-1 (Strasser et al, 1990;Acton et al, 1992). The development of an antagonist capable of inhibiting all functional homologues of Bcl-2 and thereby enhancing sensitivity to apoptosis therefore holds great promise for the treatment of neoplastic disease, particularly in combination with other therapeutic regimes.…”
Section: Discussionmentioning
confidence: 99%
“…The capacity of pim-1 and myc to synergize in lymphomagenesis was most convincingly shown with crosses of Em-pim-1 and Em-myc transgenic mice which resulted in development of lymphoid malignancies already in utero (MoÈ roÈ y et al, 1991;Verbeek et al, 1991). pim-1 has been shown to cooperate in lymphomagenesis also with bcl-2 (Acton et al, 1992), suggesting that overexpression of pim-1 can enhance or complement the e ects of two types of oncogenes that either promote cell proliferation (myc) or cell survival (bcl-2). While the mechanisms of oncogene cooperation still remain unclear, experimental evidence indicates that Pim-1 can enhance the activity of some transcription factors such as c-Myb (Leverson et al, 1998) and NFATc1 (EM Rainio, J Sandholm and PJ Koskinen, in preparation).…”
Section: Introductionmentioning
confidence: 99%
“…Based on this idea, one could clearly understand why Pim-1 cooperates with c-Myc both in apoptosis and transformation. Moreover, it provides a better explanation for the recent observation that Bcl-2 cooperates with Pim-1 in lymphomagenesis in transgenic mice (Acton et al, 1992). If one assumes that Pim-1 contributes to lymphomagenesis solely by inhibiting apoptosis, it would be rather di cult to understand why Pim-1 should so e ciently cooperate with an antiapoptotic protein Bcl-2 to transform cells.…”
Section: Discussionmentioning
confidence: 97%